alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

31,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 26–50 of 97 studies with an author at University of Pittsburgh (US) of type cohort or longitudinal study (page 2 of 4) · 31,780 in the whole library · How the 0–100 score works

Download bibliography of these 97 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 17,251 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 67 out of 100. JAMA neurology 2023-12-01

Data from 3960 MRI sessions among 1141 participants were included: 252 pathogenic variant carriers from DIAN (mean [SD] age, 38.4 [11.2] years; 137 [54%] female), 571 older adults from ADNI (mean [SD] age, 72.8 [7.3] years; 274 [48%] female), and 318 older adults from HABS (mean [SD] age, 72.4 [7.6] years; 194 [61%] female). 3 key findings →

Design: cohort study Participants: 1,141 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Microglia modulate Aβ-dependent astrocyte reactivity in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Nature Neuroscience 2025-11-06

Experimental evidence suggests that activated microglia induce astrocyte reactivity in neurodegenerative disorders, such as Alzheimer's disease (AD). 3 key findings →

Design: cohort Participants: 352 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Neurology 2006-08-01

Longitudinal studies will be required to determine the association of elevated [(11)C]PIB binding and risk of developing dementia of the Alzheimer type. 2 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA neurology 2022-10-01

Among 580 participants (PREVENT-AD, 128; HABS, 153; AIBL, 48; Knight ADRC, 251), mean (SD) age ranged from 67 (5) to 76 (6) years across cohorts, with between 55% (137/251) and 74% (95/128) female participants. 2 key findings →

Design: cohort study Participants: 580 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Archives of neurology 2012-09-01

Among well-functioning older adults, DM and poor glucose control among those with DM are associated with worse cognitive function and greater decline. 5 key findings →

Design: cohort study Participants: 717 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Archives of neurology 2003-10-01

The development of MCI is associated with measurements of cognition and depression, racial and constitutional factors, and cerebrovascular disease. 5 key findings →

Design: longitudinal study Participants: 927 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Journal of Alzheimer's disease reports 2021-06-03

This fifteen-year study provides a large database of highly characterized individuals with longitudinal cognitive, imaging and lifestyle data and biofluid collections, to aid in the development of interventions to delay onset, prevent or treat AD. 1 key finding →

Design: cohort study Participants: 1,112 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Temporal Dynamics and Biological Variability of Alzheimer Biomarkers

✓ Peer-reviewed alzhub usefulness score 65 out of 100. JAMA neurology 2025-02-17

Among the plasma biomarkers, phosphorylated tau (p-tau) 217 exhibited the highest concordance rate with Aβ (2326 of 2571 [90.5%]) and tau (100 of 120 [83.3%]) PET. 4 key findings →

Design: cohort study Participants: 2,611 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cross-Sectional and Longitudinal Associations of Neighborhood Disadvantage With Fluid Biomarkers of Neuroinflammation and Neurodegeneration

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Neurology 2025-06-25

Greater neighborhood disadvantage was associated with elevated inflammatory and AD CSF biomarkers cross-sectionally and longitudinal increases in a nonspecific inflammatory blood biomarker. 5 key findings →

Design: longitudinal study Participants: 334 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Tight glycemic control and use of hypoglycemic medications in older veterans with type 2 diabetes and comorbid dementia

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Diabetes care 2015-01-15

Older adults with diabetes and dementia are at increased risk for hypoglycemia and other adverse events associated with tight glycemic control and are unlikely to experience long-term benefits. 4 key findings →

Design: cohort study Participants: 15,880 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Incidence and prevalence of dementia in the Cardiovascular Health Study

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Journal of the American Geriatrics Society 2004-02-01

Classification resulted in 227 persons with prevalent dementia at entry into the study and 480 incident cases during follow-up. 4 key findings →

Design: cohort study Participants: 227 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Evaluation of dementia in the cardiovascular health cognition study

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Neuroepidemiology 2003-01-01

The CHS has developed a methodology for longitudinal studies of dementia in large cohorts and represents the largest study of dementia including cognitive testing, MRI and genetic markers. 1 key finding →

Design: longitudinal study Participants: 5,888 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 64 out of 100. JAMA network open 2019-12-02

The amyloid/tau/neurodegeneration (A/T/N) framework uses cerebrospinal fluid (CSF) levels of total tau (tTau) as a marker of neurodegeneration and CSF levels of phosphorylated tau 181 (pTau181) as a marker of tau tangles. 4 key findings →

Design: cohort study Participants: 465 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Sleep architecture and dementia risk in adults: an analysis of 5 cohorts from the Sleep and Dementia Consortium

✓ Peer-reviewed alzhub usefulness score 64 out of 100. SLEEP 2025-05-16

The pooled sample comprised 4657 participants (30% women) aged ≥ 60 years (mean age was 74 years at sleep assessment). 5 key findings →

Design: cohort study Participants: 2,374 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Nature medicine 2022-08-11

Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer's disease are needed to facilitate the initial screening process of participants in disease-modifying trials. 3 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source

Association between late-life body mass index and dementia: The Kame Project

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Neurology 2009-05-01

Higher baseline body mass index (BMI) and slower declining BMI in late life are associated with a reduced risk of dementia, suggesting that low BMI or a faster decline in BMI in late life may be preclinical indicators of an underlying dementing illness, especially for those who were initially overweight or obese. 3 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

High blood pressure accelerates gait slowing in well-functioning older adults over 18-years of follow-up

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Journal of the American Geriatrics Society 2011-03-01

High BP accelerates gait slowing in well-functioning older adults over a long period of time, even for those who control their BP or develop hypertension later in life. 4 key findings →

Design: cohort study Participants: 2,733 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Delirium is independently associated with poor functional recovery after hip fracture

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Journal of the American Geriatrics Society 2000-06-01

Delirium is common, persistent, and independently associated with poor functional recovery 1 month after hip fracture even after adjusting for prefracture frailty. 3 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The striatum is an early, accurate indicator of amyloid burden using [11C]PiB in Down syndrome: comparison of two radiotracers

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2024-12-06

Adults with Down syndrome demonstrate striatum-first amyloid accumulation with [ 11 C]PiB PET imaging, which has not been replicated with [ 18 F]florbetapir (FBP). 4 key findings →

Design: longitudinal study Participants: 175 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Predictors of nursing facility admission: a 12-year epidemiological study in the United States

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Journal of the American Geriatrics Society 2004-03-01

Dementia emerged as the most potent risk factor for institutionalization in this 12-year community-based epidemiological study. 3 key findings →

Design: longitudinal study Participants: 1,147 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomized / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multicenter collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 31,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,780 records, built mostly from automated pulls of Europe PMC (66% of the library) and OpenAlex (16%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,052 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events